TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07599813: A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Sponsor: Apollo Therapeutics Ltd · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 280 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,986,600

Rescue Site Savings

+$1,315,800

Unlock Full NCT07599813 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07599813 Rescue Dossier →